Mekonos is developing a new approach for non-viral cell programing using a proprietary silicon chip technology (code named: KAREL) that delivers biomaterial or molecules into potentially, millions of individual cells on a massively parallel scale. This will see a dramatic breakthrough in the genetic engineering treatment of diseases such as cancers and variety of rare genetic disorders. Instead of the more traditional method of using viruses which has major safety concerns and are very expensive, our safe, precise and fast silicon based technology, when fully developed will result in at least a 50x cost reduction and a 1000x throughput improvement over competitors

Learn more about Mekonos:









Mekonos's EIR: Louise Kirkbride 

Posted on May 22, 2017 .